标题：益血生胶囊对非霍奇金淋巴瘤患者化疗后免疫功能的影响

      作者：付岭，成雪，刘金梅    开滦总医院血液科，河北 唐山 063000

      卷次： 2019年30卷8期

      【摘要】 目的 观察益血生胶囊对非霍奇金淋巴瘤患者化疗后免疫功能的影响。方法 选取开滦总医院2016年1月至2018年8月住院收治的80例确诊非霍奇金淋巴瘤患者为研究对象，依据患者意愿是否服用益血生胶囊进行分组，其中对照组34例，观察组46例，对照组患者接受6个疗程标准CHOP方案化疗，化疗后骨髓抑制期给予对症提升细胞治疗，观察组在对照组基础上加用益血生胶囊，两组患者治疗前及第6个疗程化疗结束后1周，各抽取外周血2 mL使用流式细胞仪检测并比较其外周血T淋巴细胞亚群(CD4+、CD8+、CD4+/CD8+)的变化，以观察患者免疫功能的改善情况。结果 观察组患者治疗后外周血CD4+、CD8+细胞数量、CD4+/CD8+值分别为(35.01±11.00)%、(37.09±9.74)%、0.94±0.85，均明显高于对照组治疗后的(23.97±8.65)%、(33.97±8.73)%、0.71±0.30，差异均具有统计学意义(P<0.05)；对照组治疗后外周血CD4+、CD8+细胞数量、CD4+/CD8+值分别为(23.97±8.65)%、(33.97±8.73)%、0.71±0.30，均低于治疗前的(39.78±11.15)%、(39.06±11.00)%、1.02±0.58，差异均有统计学意义(P<0.05)；而观察组患者治疗前后的上述指标比较差异均无统计学意义(P>0.05)。结论 益血生胶囊可改善非霍奇金淋巴瘤患者免疫功能，疗效确切。
      【关键词】 益血生胶囊；非霍奇金淋巴瘤；化疗；免疫功能；改善
      【中图分类号】 R733.4 【文献标识码】 A 【文章编号】 1003—6350（2019）08—1039—03

Effect of Yixuesheng Capsule on immune function in non-Hodgkin lymphoma patients after chemotherapy.
FULing, CHENG Xue, LIU Jin-mei. Department of Hematology, Kailuan General Hospital, Tangshan 063000, Hebei, CHINA
【Abstract】 Objective To observe the effect of Yixuesheng Capsule on immune function in non-Hodgkin lym-phoma patients after chemotherapy. Methods A total of 80 patients with confirmed non-hodgkin lymphoma were se-lected as subjects, who were hospitalized in Kailuan General Hospital from January 2016 to August 2018. According tothe patient's willingness to take Yixuesheng Capsule, they were divided into control group (n=34) and observation group(n=46). The control group received 6 courses of standard CHOP chemotherapy and treated with symptomatic lifting celltherapy during the bone marrow suppression period after chemotherapy; the observation group was furtherly treated withYixuesheng Capsule on the basis of the control group. Before treatment and 1 week after the end of 6 courses of chemo-therapy, 2 mL of peripheral blood was taken from each group and then detected by flow cytometry to compare the chang-es of peripheral blood T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+) and to observe the improvement of the patient'simmune function. Results After treatment, the number of CD4+, CD8+ cells and the ratio of CD4+/CD8+ in peripheralblood in the observation group were respectively (35.01±11.00)%, (37.09±9.74)%, and (0.94±0.85), which were higherthan corresponding (23.97±8.65)%, (33.97±8.73)%, and (0.71±0.30) in the control group; all differences were statistical-ly significant (P<0.05). In the control group, the number of CD4+, CD8+ cells and the ratio of CD4+/CD8+ in peripheralblood after treatment were respectively (23.97±8.65)%, (33.97±8.73)%, and (0.71±0.30), which were lower than corre-sponding (39.78±11.15)%, (39.06±11.00)%, and (1.02±0.58) before treatment (P<0.05); while in the observation group,there were no statistically significant differences in the above mentioned indicators between patients before and aftertreatment (P>0.05). Conclusion Yixuesheng Capsule can improve the immune function of patients with non- Hodgkinlymphoma, and the curative effect is exact.
      【Key words】 Yixuesheng Capsule; Non-Hodgkin lymphoma; Chemotherapy; Immune function; Improve·短篇论著·doi:10.3969/j.issn.1003-6350.2019.08.025